Navigation Links
Cornerstone Pharmaceuticals Announces The Journal of Molecular Medicine's Publication of Research Showing Selective Inhibition of Cancer Cell Energy Metabolism With Its Novel Lipoate Derivative Compounds

CRANBURY, N.J., July 25, 2011 /PRNewswire/ -- Cornerstone Pharmaceuticals, Inc., (, a leader in the growing field of cancer metabolism-based therapeutics, today announced the publication of a paper in The Journal of Molecular Medicine ( describing the selective inhibition of cancer cell energy metabolism by its novel lipoate derivative compounds.  Specifically, the publication illuminates the mechanism by which CPI-613, a lipoic acid analog, selectively attacks the regulatory aspects of tumor cell mitochondrial metabolism, activating both apoptotic (programmed cell death) and non-apoptotic (necrosis-like) cell death pathways.  This research was conducted in collaboration between scientists at Stony Brook University and Cornerstone Pharmaceuticals. The paper "Non-redox-active lipoate derivatives disrupt cancer cell mitochondrial metabolism and are potent anti-cancer agents in vivo" is available today in the advanced online publication of The Journal of Molecular Medicine. The full author's version of the paper is available here:

"The highly reconfigured metabolism of cancer cells has recently gained wide attention as a possible source of novel drug targets," said Dr. Zuzana Zachar, Ph.D., the lead author of the paper who is Director of Research at Cornerstone and a Research Assistant Professor at Stony Brook University School of Medicine.  

"CPI-613 attacks cancer cell metabolism in a powerful new way, yielding very strong anti-cancer effects in pre-clinical human tumor models," added Dr. Paul Bingham, Ph.D., co-author, and Vice President of Research at Cornerstone and Associate Professor at Stony Brook University School of Medicine.

CPI-613 is the lead drug candidate from Cornerstone's Altered Energy Metabolism Directed (AEMD) platform.  Dr. Zachar's paper states that CPI-613 induces cancer-specific regulatory hyper-phosphorylation of the E1 subunits of the centrally important TCA enzyme complex, pyruvate dehydrogenase (PDH), resulting in the inhibition of PDH function.  These and related cancer-specific effects of the drug lead to catastrophic disruption of tumor mitochondrial metabolism. Tumor cells are thereby starved of energy and biosynthetic intermediates, culminating in cell death.  

The paper also reports that CPI-613 is a potent inhibitor of human tumor growth in pre-clinical animal models, producing apparent tumor clearance in some animals.  CPI-613 strongly inhibits tumor growth in a non-small cell human lung cancer and a human pancreatic cancer pre-clinical mouse tumor model.  In the pancreatic model, treated animals were further examined for long term survival after completion of a brief treatment regimen and a substantial fraction showed no tumor regrowth.

Robert Shorr, CEO, added "This research demonstrates that our active analogs of lipoic acid can act as potent anti-cancer agents that are highly selective in animal models by disrupting the activity of at least one key bioenergetic enzyme.  In view of the novel mechanism of action of these drugs and their potency in pre-clinical models, it is of great interest to assess their efficacy in human clinical trials and to be able to predict which patients will be most likely to benefit."

"Alterations in cancer cell metabolism are distinctive hallmarks of cancer and represent a new frontier in the development of novel and selective classes of chemotherapeutic interventions for use in the treatment of cancer.  Candidates for application of this new approach are so far, very few and lipoate analogs such as CPI-613 represent a promising new addition," said Dr. Bob Weinberg, a member of Cornerstone's scientific advisory board and a founder and member of the Whitehead Institute at MIT.

Cornerstone's proprietary Altered Energy Metabolism Directed (AEMD) drug platform disrupts biochemical alterations in the conversion of glucose to energy that occur in many types of cancer cells. These essential "bioenergetic" differences are linked to pathways that control, among other things, cancer cell growth and development, as well as various forms of cell death, including apoptosis and necrosis. The platform is designed to produce drugs, such as the company's lead drug CPI-613, that disrupt energy-production pathways whose organization or regulation are altered specifically in cancer cells. CPI- 613 is currently being evaluated in several ongoing Phase I/II trials.

About Cornerstone Pharmaceuticals

Cornerstone Pharmaceuticals, Inc. is a privately held company that is committed to changing the way cancer is treated through the discovery and development of innovative therapies capitalizing on the unique metabolic processes of cancer cells. The company's founding members, management and scientific advisory team include pre-eminent scientists focused on cancer cell metabolism, cancer research and drug development. The company's unique approach to targeting cancer metabolism has led to the discovery of first-in-class drugs with the potential to transform the way cancer is treated.

This release contains forward-looking statements. These statements relate to future events or each company's future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.

Media Contact: Meghan Weber
Liza Sullivan & Associates
(917) 399-8713

SOURCE Cornerstone Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Wake Forest Baptist Medical Center and Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial of CPI-613 in Acute Myeloid Leukemia
2. Cornerstone Pharmaceuticals Announces Positive Results of Emulsiphan Safety Study
3. Cornerstone Therapeutics to Host Fourth Quarter and Full Year 2010 Conference Call
4. Cornerstone Therapeutics to Host Third Quarter 2010 Conference Call
5. Cornerstone Therapeutics Announces Development of Generic for Tussionex®
6. Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept
7. Cornerstone Therapeutics Announces Collaboration with The Cough Company
8. Cornerstone Therapeutics to Host Second Quarter 2010 Conference Call
9. Cornerstone Therapeutics Announces Management Change
10. Cornerstone Therapeutics To Present at Deutsche Banks 35th Annual Healthcare Conference
11. Cornerstone Therapeutics to Host First Quarter 2010 Conference Call
Post Your Comments:
(Date:11/30/2015)... 30, 2015 Diplomat Pharmacy, Inc. (NYSE: ... the Detroit Free Press as a Top Workplace , ... to work for in 2015. ... 100 winners annually, based on employee surveys rating company leadership, ... Workplaces are based solely on employee feedback. The survey is ...
(Date:11/30/2015)... , Nov. 30, 2015  IBA Molecular North America, ... distribution of radiopharmaceuticals, announced that as of January 1, ... (Zevacor Pharma). The decision to rebrand the company reflects ... as well as its close relationship with Zevacor Molecular.  ... Health and Science (IHS). Peter Burke ...
(Date:11/30/2015)... 30, 2015 Baxalta Incorporated (NYSE: ... dedicated to delivering transformative therapies to patients ... today announced the launch and first shipments ... extended circulating half-life recombinant factor VIII (rFVIII) ... ADVATE [Antihemophilic Factor (Recombinant)]. The treatment was ...
Breaking Medicine Technology:
(Date:11/30/2015)... , ... November 30, 2015 , ... According to Los ... people to overeat are not necessarily caused by real hunger, but instead by ... needs food. He notes that, while many patients are aware that weight loss surgery ...
(Date:11/30/2015)... ... November 30, 2015 , ... A record crowd gathered at the ... organized by the Baruch S. Blumberg Institute. , The institute, which is the research ... science and biotechnology leaders for the conference, which focused on ways companies can work ...
(Date:11/30/2015)... ... November 30, 2015 , ... A novel class of antimicrobials ... effective in fighting methicillin-resistant Staphylococcus aureus (MRSA), one of the major drug-resistant bacterial ... small molecule analogs that target the functions of SecA, a central part of ...
(Date:11/30/2015)... NJ (PRWEB) , ... November 30, 2015 , ... ... top choice for innovative, patient centered orthopedic care. Led by John Vitolo, ... your injury or chronic condition, the team at Advocare Orthopedic & Sports Medicine ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... specializes in general dentistry out of Glen Ridge, NJ. He has both ... to achieve optimal mastication. He is also an expert in cosmetic dentistry. ...
Breaking Medicine News(10 mins):